Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers

Abstract

AIMTo determine if 30-d of oral spore-based probiotic supplementation could reduce dietary endotoxemia.METHODSApparently healthy men and women (n = 75) were screened for post-prandial dietary endotoxemia. Subjects whose serum endotoxin concentration increased by at least 5-fold from pre-meal levels at 5-h post-prandial were considered “responders” and were randomized to receive either placebo (rice flour) or a commercial spore-based probiotic supplement [Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, and Bacillus licheniformis, and Bacillus clausii] for 30-d. The dietary endotoxemia test was repeated at the conclusion of the supplementation period. Dietary endotoxin (LAL) and triglycerides (enzymatic) were measured using an automated chemistry analyzer. Serum disease risk biomarkers were measured using bead-based multiplex assays (Luminex and Milliplex) as secondary, exploratory measures.RESULTSData were statistically analyzed using repeated measures ANOVA and a P < 0.05. We found that spore-based probiotic supplementation was associated with a 42% reduction in endotoxin (12.9 ± 3.5 vs 6.1 ± 2.6, P = 0.011) and 24% reduction in triglyceride (212 ± 28 vs 138 ± 12, P = 0.004) in the post-prandial period Placebo subjects presented with a 36% increase in endotoxin (10.3 ± 3.4 vs 15.4 ± 4.1, P = 0.011) and 5% decrease in triglycerides (191 ± 24 vs 186 ± 28, P = 0.004) over the same post-prandial period. We also found that spore-based probiotic supplementation was associated with significant post-prandial reductions in IL-12p70 (24.3 ± 2.2 vs 21.5 ± 1.7, P = 0.017) and IL-1β (1.9 ± 0.2 vs 1.6 ± 0.1, P = 0.020). Compared to placebo post supplementation, probiotic subject had less ghrelin (6.8 ± 0.4 vs 8.3 ± 1.1, P = 0.017) compared to placebo subjects.CONCLUSIONThe key findings of the present study is that oral spore-based probiotic supplementation reduced symptoms indicative of “leaky gut syndrome”.

Probiotic Bacillus Spores Protect Against Acetaminophen Induced Acute Liver Injury in Rats

“…Thus, APAP in high doses may increase endotoxemia, which could, in turn, increase systemic inflammation. It was demonstrated that supplementation with a spore-based probiotic (Bacillus sp) reduced the characteristic symptoms of leaky gut syndrome [35] which suggests that our study product (MSB) may strengthen the intestinal barrier and therefore decrease the dissemination of microbial-derived compounds from the intestine (including toxins) due to inflammation-triggered leaky gut, ultimately decreasing endotoxemia. Moreover, by restoring the intestinal barrier, MSB may prevent inflammation.…”

An overview on the interplay between nutraceuticals and gut microbiota

“…However, there are spore probiotics that have the capacity to survive the harsh gastric passage and enter the intestines completely viable. As a result, bacterial spores are the only strains that have been shown to treat ME ( McFarlin et al, 2017 ; Zhou, 2017 ).…”

Current Megatrends in Food Production Related to Microbes

“…As like the LAB, also several members of the genus Bacillus have been used as probiotics. Some of them tend to inhibit the slow inflammatory processes caused by various Gram-negative endotoxins [42]. Similarly, many other microbial strains could be used as future preventive means against different health problems.…”